SAMSRITA LABS LIMITED (SAMSRITA.BO)
INR 24.14
(0.0%)
INR 24.14
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | - INR | -100.0% |
| 2022 | 216 Thousand INR | -3.8% |
| 2021 | 224.54 Thousand INR | 73.09% |
| 2020 | 129.72 Thousand INR | -99.09% |
| 2019 | 14.31 Million INR | -24.86% |
| 2018 | 19.05 Million INR | 209.0% |
| 2017 | 6.16 Million INR | -51.85% |
| 2016 | 12.8 Million INR | -65.33% |
| 2015 | 36.94 Million INR | -6.99% |
| 2014 | 39.72 Million INR | 0.0% |
| 2013 | - INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | - INR | 0.0% |
| 2023 Q4 | - INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | - INR | 0.0% |
| 2023 Q3 | - INR | 0.0% |
| 2023 FY | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 216 Thousand INR | 0.0% |
| 2022 Q2 | - INR | 0.0% |
| 2022 FY | 216 Thousand INR | -3.8% |
| 2022 Q3 | - INR | 0.0% |
| 2021 Q1 | - INR | 0.0% |
| 2021 FY | 224.54 Thousand INR | 73.09% |
| 2021 Q4 | 225 Thousand INR | 0.0% |
| 2021 Q3 | - INR | 0.0% |
| 2021 Q2 | - INR | 0.0% |
| 2020 FY | 129.72 Thousand INR | -99.09% |
| 2019 FY | 14.31 Million INR | -24.86% |
| 2018 FY | 19.05 Million INR | 209.0% |
| 2017 FY | 6.16 Million INR | -51.85% |
| 2016 FY | 12.8 Million INR | -65.33% |
| 2015 FY | 36.94 Million INR | -6.99% |
| 2014 FY | 39.72 Million INR | 0.0% |
| 2013 FY | - INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 31.27 Million INR | 100.0% |
| Biocon Limited | 147.55 Billion INR | 100.0% |
| Blue Jet Healthcare Limited | 7.11 Billion INR | 100.0% |
| Concord Biotech Limited | 10.16 Billion INR | 100.0% |
| Dishman Carbogen Amcis Limited | 26.15 Billion INR | 100.0% |
| FERMENTA BIOTECH LIMITED | 3.35 Billion INR | 100.0% |
| GENOMIC VALLEY BIOTECH LIMITED | 1.65 Million INR | 100.0% |
| Lyka Labs Limited | 1.05 Billion INR | 100.0% |
| Panacea Biotec Limited | 5.51 Billion INR | 100.0% |
| Servoteach Industries Limited | - INR | NaN% |
| SMS Lifesciences India Limited | 3.05 Billion INR | 100.0% |
| Supriya Lifescience Limited | 5.7 Billion INR | 100.0% |
| Syngene International Limited | 34.88 Billion INR | 100.0% |
| TAKE Solutions Limited | 656.08 Million INR | 100.0% |
| Titan Biotech Limited | 1.64 Billion INR | 100.0% |
| Transgene Biotek Limited | 2.34 Million INR | 100.0% |
| Vanta Bioscience Limited | 97.22 Million INR | 100.0% |